Elliot Hershberg is a venture investor at Not Boring Capital who maintains an active Stanford PhD in genomics while investing, making him a rare "working scientist–investor" rather than a former scientist who left the lab entirely. He runs The Century of Biology, a technical Substack that has become essential reading for founders and scientists, where his deal flow and investment theses connect directly to the companies and topics he features.

• Passionate about artificial intelligence and digital biology as a generational opportunity that provides highly defensible moats. Bets both a research and investment career on this space, showing particular enthusiasm for computational protein design for antibodies and GPU accelerated biology, recently attending the Cold Spring Harbor Laboratory symposium exclusively dedicated to the subject.
• Interested in next generation cell therapies and precision cancer treatments, specifically addressing the massive challenge of moving beyond blood cancers to achieve similar results for solid tumors using multiple genetic modules. Demonstrated this thesis by investing in Waypoint Bio to support their highly efficient AI powered discovery platform for cell therapies.
• Focused on biotech infrastructure and the rapid compounding of foundational tools like proteomics, microscopy, and gene editing. Firmly believes that better foundational tools allow scientists to express their ideas much faster, highlighting advancements like a new technique from the Arc Institute that drastically reduces sequencing costs while increasing cellular resolution.
• Dedicated to expanding the venture firm Amplify Bio by partnering with brilliant technical founders and scaling their active portfolio. Operates with an acute awareness that the biotech venture capital landscape has shifted toward much lower risk tolerance, requiring a heavy emphasis on mitigating absolute failure compared to traditional technology investing.
• Attentive to resilient clinical development and breakthrough vaccines, heavily praising companies that successfully navigate extreme regulatory uncertainty to reach clinical trials. Highlighted portfolio company Centivax for pushing a universal flu vaccine into human trials and attracting tens of millions in funding despite a difficult financing environment.